Oral linagliptin tablets, DPP-4 inhibitors, for managing type 2 diabetes in adults. Supplied by drug manufacturers to global distributors, hospitals, and community pharmacies. Procurement professionals acquire them for integration into therapeutic regimens in endocrine and general practice settings.